Circadian Secretion of the Intestinal Hormone GLP-1 by the Rodent L Cell

Gil-Lozano, Manuel; Mingomataj, Erli L.; Wu, W. Kelly; Ridout, Sean A.; Brubaker, Patricia L.
November 2014
Diabetes;Nov2014, Vol. 63 Issue 11, p3674
Academic Journal
Peripheral clocks are known to modulate circadian patterns of insulin secretion. GLP-1 is an incretin hormone produced by the intestinal L cell that acts as a link between the gut and pancreatic b-cell. Herein, we demonstrate the existence of a diurnal rhythm in GLP-1 secretory responses to an oral glucose load in rats, with increased release immediately preceding the normal feeding period. This profile of GLP-1 release correlated with the pattern in insulin secretion, and both rhythms were completely inverted in animals subjected to a 12-h feeding cycle disruption and abolished in rats maintained under constant light conditions. A daily variation in the insulin response to exogenous GLP-1 was also found. Consistent with these in vivo findings, we demonstrated a circadian pattern in the GLP-1 secretory response to different secretagogues in murine GLUTag L cells, as well as in the mRNA levels of several canonical clock genes. Furthermore, significant changes in the expression of several genes were demonstrated by microarray and knockdown of two of them, thyrotroph embryonic factor and protein tyrosine phosphatase 4a1, resulted in altered GLP-1 secretion. Collectively, these results indicate that an independent peripheral clock in the L cell drives a circadian rhythm in GLP-1 secretory responses.


Related Articles

  • Combined Therapy with a DPPIV Inhibitor and Nateglinide Improves Hepatic Insulin Resistance and β Cell Function in Zucker Fatty Rats on a High-Fat Diet. Kitahara, Yoshiro; Kajioka, Toshifumi; Miura, Kyoko // Diabetes;Jun2007 Supplement 1, Vol. 56, pA370 

    In addition to regulation of islet hormones and pancreatic β cell mass, GLP-1 is known to improve hepatic insulin sensitivity. Nateglinide (NT) stimulates early-phase insulin secretion into the portal vein and also improves hepatic glucose metabolism. Thus, it is predicted that the...

  • Glucagon-Like Peptide-1 Triggers Protective Pathways in Pancreatic Beta-Cells Exposed to Glycated Serum. Puddu, Alessandra; Sanguineti, Roberta; Durante, Arianna; Nencioni, Alessio; Mach, François; Montecucco, Fabrizio; Viviani, Giorgio L. // Mediators of Inflammation;2013, Vol. 2013, p1 

    Advanced glycation end products (AGEs) might play a pathophysiological role in the development of diabetes and its complications. AGEs negatively affect pancreatic beta-cell function and the expression of transcriptional factors regulating insulin gene. Glucagon-like peptide-1 (GLP-1), an...

  • Incretin-Based Therapy of Type 2 Diabetes Mellitus. Knop, Filip K.; Vilsb�ll, Tina; Holst, Jens J. // Current Protein & Peptide Science;Feb2009, Vol. 10 Issue 1, p46 

    This review article focuses on the therapeutic potential of the incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), in treating type 2 diabetes mellitus (T2DM). T2DM is characterized by insulin resistance, impaired glucose-induced insulin...

  • Glucagon-Like Peptide 1 Induces Differentiation of Islet Duodenal Homeobox-1--Positive... Hongxiang Hui; Wright, Chris; Perfetti, Riccardo // Diabetes;Apr2001, Vol. 50 Issue 4, p785 

    Investigates the ability of glucagon-like peptide 1 (GLP-1) to differentiate islet duodenal homeobox-1-positive (IDX-1) ductal cells into insulin-secreting cells. Negation of IDX-1 differentiation in human cell lines; Morphological changes of human and rat cell lines induced by GLP-1; Ability...

  • The Incretin Approach for Diabetes Treatment. Holst, Jens Juul; Ørskov, Cathrine // Diabetes;Dec2004 Supplement, Vol. 53, pS197 

    Glucagon-like peptide (GLP)-1 is a gut hormone that stimulates insulin secretion, gene expression, and β-cell growth. Together with the related hormone glucose-dependent insulinotropic polypeptide (GIP), it is responsible for the incretin effect, the augmentation of insulin secretion after...

  • DPP-IV inhibitors: A review of sitagliptin, vildagliptin, alogliptin, and saxagliptin. Miller, Shannon A.; St. Onge, Erin L.; Taylor, James R. // Formulary;Apr2008, Vol. 43 Issue 4, p122 

    Dipeptidyl peptidase IV (DPP-IV) inhibitors, including sitagliptin, vildagliptin, alogliptin, and saxagliptin, represent a novel approach in the management of type 2 diabetes. DPP-IV inhibitors reduce the rapid degradation of glucagon-like peptide-1 (GLP-1), an incretin hormone that stimulates...

  • Suppression of Pdx-1 perturbs proinsulin processing, insulin secretion and GLP-1 signalling in INS-1 cells. Wang, H.; Iezzi, M.; Theander, S.; Antinozzi, P.; Gauthier, B.; Halban, P.; Wollheim, C. // Diabetologia;Apr2005, Vol. 48 Issue 4, p720 

    Aims/hypothesis: Mutations in genes encoding HNF-4oc, HNF- 1 a and IPF- 1/Pdx- 1 are associated with, respectively, MODY subtypes-i, -3 and -4. Impaired glucose- stimulated insulin secretion is the common primary defect of these monogenic forms of diabetes. A regulatory circuit between these...

  • Glucagon-Like Peptide 1 Induces Pancreatic Î’-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor. Buteau, Jean; Foisy, Sylvain; Joly, Erik; Prentki, Marc // Diabetes;Jan2003, Vol. 52 Issue 1, p123 

    We previously provided evidence that glucagon-like peptide 1 (GLP-1) induces pancreatic β-cell growth nonadditively with glucose in a phosphatidylinositol (PI) 3-kinase- and protein kinase C ζ-dependent manner. However, the exact mechanism by which the GLP-1 receptor (GLP-1R), a member of...

  • Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Defficient Beta-Cell Mass. Portha, Bernard; Tourrel-Cuzin, Cécile; Movassat, Jamileh // Experimental Diabetes Research;2011, Special section p1 

    Recent preclinical studies in rodent models of diabetes suggest that exogenous GLP-1R agonists and DPP-4 inhibitors have the ability to increase islet mass and preserve beta-cell function, by immediate reactivation of beta-cell glucose competence, as well as enhanced beta-cell proliferation and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics